Immunotherapy in Melanoma | Specialty

The OncLive Immunotherapy in Melanoma condition center page is a comprehensive resource for clinical news and expert insights on available and investigational immunotherapies in melanoma and other skin cancers. This page features news articles, interviews in written and video format, and podcasts that focus on updates with checkpoint inhibitors and the ongoing research with this type of treatment.

Dr. Zamarin on Immunotherapy as a Staple in the Future of Cancer Treatment

October 27th 2016

Dmitriy Zamarin, MD, PhD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the ways in which immunotherapy is slated to play a major role in multiple cancer types.

Lead Researcher Discusses Promising Antibody-Drug Conjugate for Ovarian Cancer

October 25th 2016

Results from an expansion cohort of a preliminary clinical trial have shown encouraging activity for a novel antibody-drug conjugate in patients with heavily pretreated advanced ovarian cancer.

Dr. Jeffery S. Weber on Sequencing of Nivolumab, Ipilimumab in Metastatic Melanoma

October 25th 2016

Jeffery S. Weber, MD, PhD, deputy director of the Laura and Isaac Perlmutter Cancer Center, co-director of the Melanoma Program, and head of Experimental Therapeutics at NYU Langone Medical Center, discuses the key takeaways from the phase II CheckMate-064 trial, in which patients were randomized to receive either nivolumab followed by ipilimumab followed by nivolumab maintenance therapy, or ipilimumab followed by nivolumab and maintenance therapy with nivolumab.

Dr. Luke on Immunotherapy Diagnostics in Melanoma

October 20th 2016

Jason Luke, MD, assistant professor of Medicine, The University of Chicago Medicine, discusses the various methods involved in immunotherapy diagnostics in the treatment landscape of melanoma.

Long-Term Follow-Up Supports Frontline Dabrafenib/Trametinib in Melanoma

October 20th 2016

Co-inhibition of BRAF and MEK pathways with dabrafenib and trametinib continued to be superior to sole BRAF inhibition with vemurafenib in patients with unresectable metastatic melanoma at 3 years.

Immunotherapy Combos, Novel Diagnostics Emerging in Melanoma

October 17th 2016

Jason Luke, MD, discusses some of the exciting research that is happening across the field of immunotherapy in melanoma, including combination strategies, novel agents, and next-generation diagnostics.

Mature Data Sustain Frontline OS Benefit of Pembrolizumab in Melanoma

October 17th 2016

A final analysis of the overall survival data from the KEYNOTE-006 trial showed that frontline pembrolizumab was superior to ipilimumab in the treatment of patients with advanced melanoma.

Dr. Robert on Next Steps Following the Phase III COMBI-v Study in Melanoma

October 14th 2016

Caroline Robert, MD, PhD, Head of Dermatology, Institute Gustave-Roussy, discusses the next steps following the results of the phase III COMBI-v study in BRAF-mutant melanoma.

Dr. Jason Luke on Potential for IDO Inhibitors in Melanoma

October 13th 2016

Jason Luke, MD, Assistant Professor of Medicine, The University of Chicago Medicine, discusses IDO inhibitors in melanoma.

Dr. Flaherty on Resistance in BRAF-Mutant Melanoma

October 11th 2016

Keith T. Flaherty, MD, director of Developmental Therapeutics at the Cancer Center of Massachusetts General Hospital, discusses resistance that develops in patients with BRAF-mutant melanoma.

Dr. Robert on the Phase III COMBI-v Study in BRAF-Mutant Melanoma

October 8th 2016

Caroline Robert, MD, PhD, Head of Dermatology, Institute Gustave-Roussy, discusses the results of the phase III COMBI-v study in BRAF-mutant melanoma during an interview at the ESMO 2016 Congress.

Adjuvant Ipilimumab Improves Survival in High-Risk Melanoma

October 8th 2016

Treatment with ipilimumab reduced the risk of death by 28% versus placebo in patients with high-risk stage III melanoma.

Thousands of Melanoma Patients in Europe Not Receiving Novel Agents

October 7th 2016

Over one-fourth of patients with metastatic melanoma in Europe do not have access to groundbreaking therapies that could extend their lives.

Dr. Kiran Turaga on Regional Therapies in Melanoma

October 7th 2016

Kiran Turaga, MD, MPH, surgical oncologist, University of Chicago Cancer Center, discuses regional therapies in melanoma.

Dr. Kaufman on T-VEC in Melanoma

October 7th 2016

Howard L. Kaufman, MD, chief surgical officer, associate director for Clinical Science, surgical oncologist, Rutgers Cancer Institute of New Jersey, discusses oncolytic immunotherapy talimogene laherparepvec (T-VEC; Imlygic) for treatment of patients with melanoma, as well as the agent's side effect profile.

Dr. Weber on Selecting Immunotherapy for Patients With Melanoma

October 5th 2016

Encorafenib/Binimetinib Combo Improves PFS Versus Vemurafenib in Phase III Melanoma Study

September 26th 2016

The combination of the BRAF inhibitor encorafenib and the MEK inhibitor binimetinib improved progression-free survival compared with single-agent vemurafenib for patients with BRAF-mutant melanoma.

Dr. Saenger on Ongoing Research in Melanoma

September 21st 2016

Yvonne Saenger, MD, director of Melanoma Immunotherapy at Columbia University Medical Center, discusses ongoing research related to immunotherapy in the field of melanoma. Sanger shared this insight during an interview with OncLive during the recent Society for Immunotherapy of Cancer Cancer Immunotherapy 101 meeting in New York City.

Dr. Antoni Ribas on the Search for Immunotherapy Biomarkers in Melanoma

September 21st 2016

Dr. Dummer on Driver Mutations and Next Steps in Melanoma

September 15th 2016

Reinhard Dummer, MD, professor, Department of Dermatology, University of Zurich Hospital, discusses driver mutations and next steps in the treatment of patients with melanoma.